BMS and Moffitt Cancer Center Enter Into a Collaboration Agreement
News Oct 03, 2015
Bristol-Myers Squibb Company and Moffitt Cancer Center have announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
As part of the I-O RPM program, Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists.
“Moffitt Cancer Center has had a long-standing commitment to immuno-oncology research, including in partnership with Bristol-Myers Squibb, and we look forward to our continued work with them as part of the I-O RPM program,” said Laura Bessen, MD, head of U.S. Medical, Bristol-Myers Squibb.
“This new partnership with Bristol-Myers Squibb will foster new Moffitt investigator-initiated studies for rare tumors and gives our faculty the opportunity to educate research students about innovative clinical trials,” said Dan Sullivan, M.D., Associate Center Director for Clinical Science at Moffitt.
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
A Greener Way to Make KetonesNews
Researchers at McGill University have discovered a new, more environmentally friendly way to make ketones, an important chemical ingredient in pharmaceuticals. While ketones are found in a wide range of useful chemicals, they are commonly prepared through energy-intensive, multi-step technologies that create significant chemical waste.READ MORE